SG301
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for SG301, covering 2025-06-27 to 2026-04-07. Get the full timeline:
Most recent: Clinical Trial Update: SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies [Phase 1]